{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:48:33Z","timestamp":1791989313333,"version":"4.4.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Large\u2010scale comprehensive studies on HBV RNA in chronic hepatitis B are lacking. We aimed to study the HBV RNA profile and its correlation with other viral markers in patients with chronic hepatitis B who are treatment\u2010na\u00efve and patients receiving nucleos(t)ide analogues (NA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results<\/jats:title>\n                    <jats:p>\n                      Biomarkers, including HBV RNA and hepatitis B core\u2010related antigen (HBcrAg), were measured in 388 patients. Of these, 246 were treatment\u2010na\u00efve and were categorized into HBeAg\u2010positive chronic infection (n\u00a0=\u00a041), HBeAg\u2010positive chronic hepatitis (n\u00a0=\u00a081), HBeAg\u2010negative chronic infection (n\u00a0=\u00a039), HBeAg\u2010negative chronic hepatitis (n\u00a0=\u00a066), and HBsAg seroclearance (n\u00a0=\u00a019). These biomarkers were also measured in 142 patients who were NA\u2010treated receiving tenofovir or entecavir at baseline, week 48, and week 96. The pattern of serum HBV RNA levels mirrored HBV DNA (1\u20102 logs higher than HBV RNA) and HBcrAg in patients who were treatment\u2010na\u00efve. HBV RNA correlated best with HBcrAg (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u00a0=\u00a00.84) and to a lesser extent with HBV DNA (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u00a0=\u00a00.737) (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). In patients with HBsAg seroclearance, 15.8% and 15.8% had detectable serum HBV RNA and HBcrAg, respectively. NA treatment reduced serum HBV RNA by 1.46 logs and 1.77 logs at weeks 48 and 96, respectively. At week 96 of NA therapy, only 19.1% patients who were tenofovir\u2010treated and 25.7% patients who were entecavir\u2010treated had unquantifiable HBV RNA (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&gt;\u00a00.05). In patients who were treated and had undetectable HBV DNA, 77.5% and 30% had quantifiable HBV RNA and HBcrAg, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HBV RNA showed distinct and corresponding profiles in patients with HBV in different disease phases. HBV RNA and HBcrAg could be used to monitor residual transcriptional activities in patients with HBsAg seroclearance. NA led to reduction of serum HBV RNA. Monitoring of viral activities can still be achieved in patients with undetectable HBV DNA by serum HBV RNA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.31616","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T22:25:47Z","timestamp":1604701547000},"page":"2167-2179","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":82,"title":["HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy"],"prefix":"10.1097","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-3935","authenticated-orcid":false,"given":"Lung\u2010Yi","family":"Mak","sequence":"first","affiliation":[{"name":"Department of Medicine,The University of Hong Kong,Queen Mary Hospital,Hong Kong,Hong Kong"},{"name":"State Key Laboratory of Liver Research,The University of Hong Kong,Hong Kong,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Cloherty","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases,Abbott Laboratories,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9078-5005","authenticated-orcid":false,"given":"Danny Ka\u2010Ho","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong,Queen Mary Hospital,Hong Kong,Hong Kong"},{"name":"State Key Laboratory of Liver Research,The University of Hong Kong,Hong Kong,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gersch","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases,Abbott Laboratories,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai\u2010Kay","family":"Seto","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong,Queen Mary Hospital,Hong Kong,Hong Kong"},{"name":"State Key Laboratory of Liver Research,The University of Hong Kong,Hong Kong,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-8902","authenticated-orcid":false,"given":"James","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong,Queen Mary Hospital,Hong Kong,Hong Kong"},{"name":"State Key Laboratory of Liver Research,The University of Hong Kong,Hong Kong,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man\u2010Fung","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Medicine,The University of Hong Kong,Queen Mary Hospital,Hong Kong,Hong Kong"},{"name":"State Key Laboratory of Liver Research,The University of Hong Kong,Hong Kong,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"hep31616-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31616-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"hep31616-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep31616-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B","volume":"14","year":"2020","journal-title":"Hepatol Int"},{"key":"hep31616-bib-0005-20250824","article-title":"Seven\u2010year treatment outcome of entecavir in a real\u2010world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"hep31616-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep31616-bib-0007-20250824","article-title":"Serum HBV RNA quantification: Useful for monitoring natural history of chronic hepatitis B infection","volume":"19","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"hep31616-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog\u2010treated or untreated patients during chronic and acute infection","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep31616-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: Hepatitis B core\u2010related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection","volume":"47","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"hep31616-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core\u2010related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","year":"2007","journal-title":"J Clin Microbiol"},{"key":"hep31616-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core\u2010related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","year":"2017","journal-title":"Liver Int"},{"key":"hep31616-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21339","article-title":"Correlation between serum hepatitis B virus core\u2010related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients","volume":"81","year":"2009","journal-title":"J Med Virol"},{"key":"hep31616-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV\u2010RNA levels and intrahepatic viral as well as histologic activity markers in entecavir\u2010treated patients","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep31616-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","year":"2013","journal-title":"J Gastroenterol"},{"key":"hep31616-bib-0015-20250824","first-page":"42","article-title":"Pre\u2010genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy","volume":"72","year":"2019","journal-title":"Hepatology"},{"key":"hep31616-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy","volume":"18","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep31616-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JCM.00760-17","article-title":"Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?","volume":"55","year":"2017","journal-title":"J Clin Microbiol"},{"key":"hep31616-bib-0018-20250824","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core\u2010related antigen in the natural history of chronic hepatitis B","volume":"20","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"hep31616-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/jvh.12688","article-title":"Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep31616-bib-0020-20250824","article-title":"Circulating pregenomic HBV RNA is primarily full\u2010length in chronic hepatitis B patients undergoing nucleos(t)ide analogue therapy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"hep31616-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of hepatitis B core\u2010related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high\u2010risk immunosuppressive therapy","volume":"111","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"hep31616-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/17512433.2019.1567327","article-title":"Novel developments of hepatitis B: Treatment goals, agents and monitoring tools","volume":"12","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"hep31616-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long\u2010term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep31616-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5009\/gnl18425","article-title":"New biomarkers of chronic hepatitis B","volume":"13","year":"2019","journal-title":"Gut Liv"},{"key":"hep31616-bib-0025-20250824","article-title":"RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"hep31616-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3\u2013778 in patients with chronic HBV infection","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep31616-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI\u2010H0731, a hepatitis B virus core inhibitor: a randomised, placebo\u2010controlled phase 1 trial","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep31616-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1016\/S0618-8278(19)30092-1","article-title":"Short term RNA interference therapy in chronic hepatitis B using JNJ\u20103989 brings majority of patients to HBsAg < 100 IU\/ml threshold","volume":"70","year":"2019","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1002\/hep.31690","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000}}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31616","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:05:32Z","timestamp":1756080332000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31616","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2020-05-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}